Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 2/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.45 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.45 |
| ▸ | HTR3B | O95264 | 1/20 | 0.45 |
| ▸ | HTR5A | P47898 | 1/20 | 0.45 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.45 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.45 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3967446 | 0.80 | MAPT (0.48) | HTR3ASIGMAR1HTR3EHTR3BHTR3D | |
| SCHEMBL3968908 | 0.76 | F2 (0.42) | RAB9AGAAAKR1C3LMNANPC1 | |
| SCHEMBL4283993 | 0.74 | POLB (0.46) | HTR3ASIGMAR1HTR3EHTR3BHTR3D | |
| SCHEMBL3969849 | 0.69 | CHRNB2 (0.43) | ALDH1A1GAACYP3A4 | |
| SCHEMBL3534699 | 0.66 | HTR3A (0.69) | HTR3ASIGMAR1HTR3EHTR3BHTR5A | |
| SCHEMBL29594813 | 0.66 | HTR3A (0.69) | HTR3ASIGMAR1HTR3EHTR3BHTR5A | |
| SCHEMBL6002185 | 0.66 | HTR3A (1.00) | HTR3ASIGMAR1HTR3EHTR3BHTR5A | |
| SCHEMBL28043610 | 0.66 | HTR3A (0.57) | HTR3ASIGMAR1HTR3EHTR3BHTR5A | |
| SCHEMBL30101946 | 0.66 | HTR3A (0.57) | HTR3ASIGMAR1HTR3EHTR3BHTR5A | |
| SCHEMBL3970586 | 0.66 | ADRA1A (0.35) | RAB9AALDH1A1GAACYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0866656-B1 | USE OF N-SUBSTITUTED PYRIDONES AS TUMOR NECROSIS FACTOR ALPHA INHIBITORS | MARGOLIN SOLOMON B (US) | 2007-04-25 | — | — | EP | claimed |
| EP-0813409-B1 | TREATMENT OF CYTOKINE GROWTH FACTOR CAUSED DISORDERS | MARGOLIN SOLOMON B (US) | 2004-05-06 | — | — | EP | claimed |
| US-5962478-A | ADMINISTERING A N-SUBSTITUTED 2(1H)PYRIDONE | INTERMUNE, INC. | 1999-10-05 | — | — | US | claimed |
| US-12023342-B2 | Aerosol pirfenidone and pyridone analog compounds and uses thereof | AVALYN PHARMA INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-20230149375-A1 | AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF | AVALYN PHARMA INC. | 2023-05-18 | — | — | US | disclosed |
| US-11559520-B2 | Aerosol pirfenidone and pyridone analog compounds and uses thereof | AVALYN PHARMA INC. (US) | 2023-01-24 | — | — | US | disclosed |
| US-20220218683-A1 | AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF | AVALYN PHARMA INC. | 2022-07-14 | — | — | US | disclosed |
| US-11224592-B2 | Aerosol pirfenidone and pyridone analog compounds and uses thereof | AVALYN PHARMA INC. (US) | 2022-01-18 | — | — | US | disclosed |
| US-11071741-B2 | Aerosol pirfenidone and pyridone analog compound and uses thereof | AVALYN PHARMA INC. (US) | 2021-07-27 | — | — | US | disclosed |
| US-20210069165-A1 | AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF | AVALYN PHARMA INC. (US) | 2021-03-11 | — | — | US | disclosed |
| US-20200405704-A1 | AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF | AVALYN PHARMA INC. (US) | 2020-12-31 | — | — | US | disclosed |
| WO-2012106382-A1 | AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF | GENOA PHARMACEUTICALS, INC. (US) | 2012-08-09 | — | — | WO | disclosed |
| US-20120192861-A1 | AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF | GENOA PHARMACEUTICALS, INC. (US) | 2012-08-02 | — | — | US | disclosed |
| US-20090286843-A1 | MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION | HOFFMANN-LA ROCHE INC. | 2009-11-19 | — | — | US | disclosed |
| US-20090111982-A1 | MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION | HOFFMANN-LA ROCHE INC. | 2009-04-30 | — | — | US | disclosed |
| US-20090105471-A1 | MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION | HOFFMANN-LA ROCHE INC. | 2009-04-23 | — | — | US | disclosed |
| US-7491794-B2 | Macrocyclic compounds as inhibitors of viral replication | INTERMUNE, INC. (US) | 2009-02-17 | — | — | US | disclosed |
| US-20060198823-A1 | Compositions and methods for treating viral infections | INTERMUNE, INC. | 2006-09-07 | — | — | US | disclosed |
| US-20050267018-A1 | Macrocyclic compounds as inhibitors of viral replication | HOFFMANN-LA ROCHE INC. | 2005-12-01 | — | — | US | disclosed |
| US-5962478-A | ADMINISTERING A N-SUBSTITUTED 2(1H)PYRIDONE | INTERMUNE, INC. | 1999-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111982-A1 | MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION | EIF2AK2, HAVCR2, ZC3HAV1 | HTR3A 4543/4885SIGMAR1 3309/4885HTR3E 3978/4885 |
| US-20230149375-A1 | AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF | PLPBP, PIR, PDXK | HTR3A 653/4885SIGMAR1 1581/4885HTR3E 1672/4885 |
| US-11224592-B2 | Aerosol pirfenidone and pyridone analog compounds and uses thereof | PLPBP, PIR, PDXK | HTR3A 653/4885SIGMAR1 1581/4885HTR3E 1672/4885 |
| US-20090286843-A1 | MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION | EIF2AK2, HAVCR2, ZC3HAV1 | HTR3A 4543/4885SIGMAR1 3309/4885HTR3E 3978/4885 |
| US-20210069165-A1 | AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF | PLPBP, PIR, PDXK | HTR3A 653/4885SIGMAR1 1581/4885HTR3E 1672/4885 |
| US-20060198823-A1 | Compositions and methods for treating viral infections | IFNAR1, IFNG, TLR3 | HTR3A 166/4885SIGMAR1 28/4885HTR3E 338/4885 |
| US-20220218683-A1 | AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF | PLPBP, PIR, PDXK | HTR3A 653/4885SIGMAR1 1581/4885HTR3E 1672/4885 |
| US-20200405704-A1 | AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF | PLPBP, PIR, PDXK | HTR3A 653/4885SIGMAR1 1581/4885HTR3E 1672/4885 |
| US-11559520-B2 | Aerosol pirfenidone and pyridone analog compounds and uses thereof | PLPBP, PIR, PDXK | HTR3A 653/4885SIGMAR1 1581/4885HTR3E 1672/4885 |
| US-20120192861-A1 | AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF | PLPBP, PIR, PDXK | HTR3A 653/4885SIGMAR1 1581/4885HTR3E 1672/4885 |
| US-20050267018-A1 | Macrocyclic compounds as inhibitors of viral replication | EIF2AK2, HAVCR2, ZC3HAV1 | HTR3A 4543/4885SIGMAR1 3309/4885HTR3E 3978/4885 |
| US-12023342-B2 | Aerosol pirfenidone and pyridone analog compounds and uses thereof | PLPBP, PIR, PDXK | HTR3A 653/4885SIGMAR1 1581/4885HTR3E 1672/4885 |
| US-20090105471-A1 | MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION | EIF2AK2, HAVCR2, ZC3HAV1 | HTR3A 4543/4885SIGMAR1 3309/4885HTR3E 3978/4885 |
| US-11071741-B2 | Aerosol pirfenidone and pyridone analog compound and uses thereof | PLPBP, PIR, PDXK | HTR3A 658/4885SIGMAR1 1650/4885HTR3E 1638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.